DGKα inhibition enhances the antitumor effect of chiauranib on transformed follicular lymphoma.

ABSTRACT: Transformed follicular lymphoma (t-FL) is a heterogeneous, aggressive B-cell malignancy with unfavorable clinical outcomes, while there is no standard and effective treatment available for t-FL. In this study, we investigated the preclinical anti-lymphoma efficacies and potential mechanism of action for a novel therapeutic strategy, combining the DGKα inhibitor ritanserin with chiauranib, a new orally bioavailable multi-target kinase inhibitor, in t-FL models. This combination therapy exhibited synergistic cytotoxicity against t-FL cells and primary B lymphoma cells, evidenced by cooperatively inducing loss of cell viability and promoting cell apoptosis. Moreover, the combination of ritanserin with chiauranib resulted in significant suppression of tumor burden in xenograft models. The syne

SUBMITTER: Huang J 

PROVIDER: S-EPMC12619788 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature